×

Biotech and Pharmaceuticals Pharmaceuticals

  • Gaining access to experimental drugs

    Scott Gottlieb, M.D., American Enterprise Institute, and Jeff Allen, Friends of Cancer Research executive director, discuss the FDA's drug approval process and the need in some cases to allow access to experimental therapies.

  • Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • Bill Ackman

    A lawsuit by Allergan says the unusual arrangement by Valeant Pharmaceuticals and activist investor Bill Ackman amounts to insider trading.

  • Medical staff put on protective gear at Kenema Government Hospital before taking a sample from a suspected Ebola patient in Kenema, Sierra Leone.

    The death toll from the Ebola virus in West Africa keeps growing to record levels. And ironically, that may be why there's no vaccine, said an expert.

  • West African leaders and international health groups have stepped up plans to combat the world’s worst outbreak of the deadly Ebola virus.

  • Catalent CEO: Leading advanced drug delivery

    John Chiminski, Catalent Pharma Solutions CEO, discusses the company's IPO and business strategy. Chiminski the company is the world's leader in advanced drug technologies.

  • Euro dampened Bayer's profits: CEO

    Marijn Dekkers, CEO of Bayer, says that operationally, the group had a "very good quarter", but that profits were dampened by the strength of the euro.

  • UPS CFO Kurt Kuehn on CNBC's Squawk on the Street on his company's decision to stop deliveries for illegal online pharmacies and pay $40 million to end a Federal criminal probe into its shipping practices. Rival FedEx was in court today fighting similar charges.

  • Ian Read, CEO, Pfizer,  leaves the House of Commons on May 14, 2014 in London.

    Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.

  • Merck & Pfizer beat the Street

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • Big pharma tax attack

    Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.

  • Pills

    What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.

  • Pfizer to renew AstraZeneca bid in November?

    Ranjith Gopinathan, programme manager, life sciences and healthcare practice at Frost & Sullivan, discusses pharmaceutical groups Merck and Pfizer ahead of their quarterly results.

  • Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.

  • A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.

  • Caterpillar CEO sees mining 'green shoots'

    Doug Oberhelman, Caterpillar chairman & CEO, weighs in on the manufacturer's fiscal second quarter of EPS $1.69 ex-items on revenues of $14.15 billion.

  • Eli Lilly looking for smaller acquisitions: CEO

    The big large-scale combinations are not right for Lilly right now, says John Lechleiter, Eli Lilly CEO, discussing how the company plans to expand its pharmaceutical footprint through acquiring smaller companies. Also Lechleiter weighs in on growing its animal health care business.

  • Results hurt by patent expirations: Eli Lilly CEO

    John Lechleiter, Eli Lilly CEO, breaks down the pharmaceutical giant's quarterly results. And Lechleiter weighs in on the benefits of investing in R&D.

  • GSK 'getting off to a slow start': Pro

    Raghuram Selvaraju, Head of Healthcare Equity Research at Aegis Capital, outlines the factors that weighed on GlaxoSmithKline's second quarter earnings.